Cadila Healthcare informs regarding USFDA inspection at Ahmedabad facility

At the end of the inspection, no observation (483) is issued, the company informed.

Dec 20, 2019 08:12 IST India Infoline News Service

Cadila Healthcare informed the exchanges that the USFDA inspected the company’s topical manufacturing facility located in Ahmedabad from 16th to 20th December, 2019.

At the end of the inspection, no observation (483) is issued.

Cadila Healthcare Ltd is currently trading at Rs265.65 up by Rs4.1 or 1.57% from its previous closing of Rs261.55 on the BSE.

The scrip opened at Rs260.90 and has touched a high and low of Rs267.65 and Rs260.30 respectively. So far 12,49,963 (NSE+BSE) shares were traded on the counter.

The current market cap of the company is Rs26,775.99cr.


Related Story